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microbiota maturation. The human ฀-defensin 2 (hBD-2) is a host defense peptide present almost ex-
clusively in epithelial tissues, with pronounced immunomodulatory properties, which has recently been
shown to ameliorate asthma and IBD in animal models. We hypothesized that adequate hBD-2 secre-
tion plays a role in the protection against asthma and allergy development and that genetic variations
in the complex gene locus coding for hBD-2 may be a risk factor for developing these diseases, if as a
consequence, hBD-2 is insufficiently produced. We used MALDI-TOF MS genotyping, sequencing and a
RFLP assay to study the genetic variation including mutations, polymorphisms and copy number vari-
ations in the locus harboring both genes coding for hBD-2 (DEFB4A and DEFB4B). We administered
hBD-2 orally in a mouse model of house dust mite (HDM)-asthma before allergy challenge to explore its
prophylactic potential, thereby mimicking a protective farm effect. Despite the high complexity of the
region harboring DEFB4A and DEFB4B we identified numerous genetic variants to be associated with
asthma and allergy in the GABRIELA Ulm population of 1,238 children living in rural areas, including
rare mutations, polymorphisms and a lack of the DEFB4A. Furthermore, we found that prophylactic
oral administration of hBD-2 significantly curbed lung resistance and pulmonary inflammation in our
HDM mouse model. These data indicate that inadequate genetic capacity for hBD-2 is associated with
increased asthma and allergy risk while adequate and early hBD-2 administration (in a mouse model)
prevents atopic asthma. This suggests that hBD-2 could be involved in the protective farm effect and
may be an excellent candidate to confer protection against asthma development.
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Asthma and allergies are complex, chronic inflammatory diseases in which genetic and
environmental factors are crucial. Protection against asthma and allergy development in
the context of farming environment is established by early animal contact, unpasteurized
milk consumption and gut microbiota maturation. The human b-defensin 2 (hBD-2) is a
host defense peptide present almost exclusively in epithelial tissues, with pronounced
immunomodulatory properties, which has recently been shown to ameliorate asthma and
IBD in animal models. We hypothesized that adequate hBD-2 secretion plays a role in the
protection against asthma and allergy development and that genetic variations in the
complex gene locus coding for hBD-2 may be a risk factor for developing these
diseases, if as a consequence, hBD-2 is insufficiently produced. We used MALDI-TOF
MS genotyping, sequencing and a RFLP assay to study the genetic variation including
mutations, polymorphisms and copy number variations in the locus harboring both
genes coding for hBD-2 (DEFB4A and DEFB4B). We administered hBD-2 orally in a
mouse model of house dust mite (HDM)-asthma before allergy challenge to explore
its prophylactic potential, thereby mimicking a protective farm effect. Despite the high
complexity of the region harboring DEFB4A and DEFB4B we identified numerous genetic
variants to be associated with asthma and allergy in the GABRIELA Ulm population of
1,238 children living in rural areas, including rare mutations, polymorphisms and a lack of
the DEFB4A. Furthermore, we found that prophylactic oral administration of hBD-2
significantly curbed lung resistance and pulmonary inflammation in our HDM mouse
model. These data indicate that inadequate genetic capacity for hBD-2 is associated with
increased asthma and allergy risk while adequate and early hBD-2 administration (in a
mouse model) prevents atopic asthma. This suggests that hBD-2 could be involved in the
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protective farm effect and may be an excellent candidate to confer protection against
asthma development.
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INTRODUCTION
Exposure to a diversity of microbes is crucial for the development
and maturation of the human immune system (1–3). Children
born and growing up in a traditional farm environment
are protected against chronic inflammatory diseases such
as asthma, allergy and inflammatory bowel diseases (IBD)
(4–6), in which epithelial barrier dysfunction plays a central
role (7–10). While the mechanism of protection is still
elusive, associations with animal contact (11), drinking of
unpasteurized milk (12) and maturation of the gut microbiota
(13) were described.
Contact of microorganisms with human surfaces induce
epithelial barrier defense mechanisms and the release of host
defense peptides (HDPs), such as b-defensins (14–16). These are
capable of eliminating a broad range of microorganisms and
fine-tune the elicited immune response in multiple diseases,
including IBD, cystic fibrosis, and rhinovirus infections (17–
19). Genetic and/or environmental disturbances in the secretory
capacity of functional HDPs may facilitate bacterial translocation
(20) and simultaneously disrupt microbial homeostasis (21),
collectively fueling systemic inflammation. Both aberrant
inflammation and early airway colonization with microbial
pathogens may predispose for childhood asthma (22). The
immunomodulatory nature of many b-defensins, combined
with their effective regulation of microbial colonization,
positions these HDPs at center stage for a causal role in the
development of inflammatory diseases and at the same time
make them promising candidates for prevention and treatment
of these diseases. Human b-defensin 2 (hBD-2), which is almost
non-existent in the unprovoked airways and gut but profoundly
abundant in inflamed epithelial tissues in response to
environmental stimuli (23–26), may be of particular interest.
Indeed, hBD-2 has recently been shown to ameliorate asthma
and IBD in animal models (17–27).
Diverse microbial exposure in early life as well as the
individual’s personal capacity to mount adequate immunological
responses seem to be crucial to avoid asthma and allergy
development (28). A significant part of the genetic susceptibility
for asthma and allergy may be driven by variation in genes
contributing to immunological processes, depending also on
differences in environmental exposure (28). While recent studies
on the subject have used genome-wide association study (GWAS)
data, crucial regions of the genome are not covered in this
approach: the genetic locus containing multiple defensin genes
including hBD-2 on chromosome 8 is one of them. Due to its
complex genetic architecture (29, 30) it is one of the few regions in
the human genome still not fully deciphered. A further obstacle in
defensin research has been the technical difficulty to produce
purified defensin for experimental studies. As hBD-2 protein only
became available in sufficient quantities recently, only a handful of
studies have investigated the role and potential of the molecule so
far (17, 27, 31, 32).
Here, we now investigated genetic variability in the extremely
complex gene locus of hBD-2; performed association studies
with some focus on farming environment exposure; and
performed mouse experiments to explore if hBD-2 could play




Study Cohort GABRIELA Ulm
To allow for the assessment of the effects of genetic variations in
DEFB4A and DEFB4B on asthma and atopy in the context of
farm environment exposure, we performed genetic association
analyses in the GABRIEL Advanced Studies (GABRIELA) from
Ulm, comprising 1,238 participants recruited in and around the
city of Ulm, Germany. The primary aim of the study was to
identify mechanisms of the protective farming effects on the
development of asthma and atopic sensitization in primary
school children from approx. 6 to 10 years of age with baseline
assessment in 2006 (33, 34). Yearly follow-up assessments were
conducted from 2010 to 2016 (35). A description of demographic
factors is given in Supplementary Table 1. Asthma was defined
as either reported wheeze in the past 12 months or ever inhaler
use for asthma or a reported doctor’s diagnosis of asthma at least
once or wheezy bronchitis at least twice throughout the lifetime.
Atopy was defined as specific IgE antibodies of at least 0.35 kU/L
against Dermatophagoides pteronyssinus, cat dander, common
silver birch, or grass mix (34). The distribution of the cohort
according to presence of asthma and/or atopy and farm exposure
is given in Supplementary Table 2.
Single Nucleotide Polymorphism (SNP) Selection
and Genotyping
To study the region on chromosome 8p23.1 containing the two
almost identical genes coding for hBD-2, DEFB4A and DEFB4B,
in detail and to retrieve information for already described/
existing gene variants, we used publicly available online tools:
Ensembl1, NCBI resources2, and the UCSC genome browser3. To
compare the transcription factor binding sites upstream of both
hBD-2 genes, we used the online tool PROMO 3.0 provided by
the Algorithmics and Genetics Group (ALGGEN) in the
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de Catalunya (Barcelona, Spain). To investigate the association
between SNPs in or nearby the DEFB4A and DEFB4B genes (10
kb downstream each copy and the 477kb section between them)
and the development of asthma and atopy, we searched for all
annotated SNPs with a minor allele frequency (MAF) ≥ 0.01 in
CEU population of the 1000 Genomes project [Utah Residents
(CEPH) with Northern and Western European Ancestry], which
were either present in a putative regulatory (e.g. promoter
region) or coding regions (or close vicinity) of the DEFB4A
and DEFB4B genes. Out of 458 reported SNPs identified in the
1000 Genomes project in this region, 40 fulfilled the described
criteria. For genotyping design, we used parameters (i.e. modified
flank size and amplicon length), which slightly deviated from the
standard ones to increase the chances of finding primers in the
highly repetitive area (Agena Assay Design Suite v2.0, Agena
Bioscience, USA). In total, only 13 out of 40 targeted SNPs
passed quality control from the in silico assay design and were
successfully genotyped in all 1,238 participants from the
GABRIELA Ulm cohort (36). Genotyping was performed using
the Sequenom MALDI-TOF mass spectrometry system in
collaboration with the Institute of Clinical Molecular Biology,
Kiel University.
Distinguishing Between DEFB4A and DEFB4B and
Copy Number Variant Analysis
To determine the presence of one or the other gene copy and to
distinguish between DEFB4A and DEFB4B, we selected 200
gender- and age-matched subjects from GABRIELA Ulm as an
exploratory cohort equally distributed between different
exposure and outcome groups (Supplementary Table 2). We
developed RFLP (Restriction Fragment Length Polymorphism)-
based assay to discriminate between DEFB4A and DEFB4B. First,
we retrieved the sequences of DEFB4A and DEFB4B from the
online genome browser Ensembl4 (37) (GRCh38.p12 primary
assembly) and aligned them using the Basic Local Alignment
Search Tool (BLAST, NCBI; U.S. National Library of Medicine,
8600 Rockville Pike, Bethesda MD, 20894 USA). We used
commercially available restriction enzymes to digest only one
of the copies after targeted PCR fragment amplification. We used
the free online tool NEBcutter V2.0 (38) to identify suitable
enzymes. We designed a primer pair framing a specific single
nucleotide difference between the two gene copies: at this
position, DEFB4B is cut by a specific restriction enzyme (Alu I,
New England Biolabs, Germany) while DEFB4A remains uncut.
As an internal positive control of the experiment, the primer pair
also included two cutting sites in both gene copies. A standard
PCR was carried out for each sample using a final DNA
concentration of 1.3 ng/µL and annealing temperature of 61°C.
The primer sequences were 5′-TGTAATGAGCATTGCACC
CAATAC-3′ (forward) and 5′-TCACAGTATAGGCTGGGC
CTTA-3′ (reverse). Digestion was conducted at 37°C for 10 h
followed by enzyme-inactivation at 80°C for 1 h. After digestion,
fragments from the two different gene copies were separated by
agarose gel-electrophoresis (Supplementary Figure 1A). As a
control for the accuracy of the RFLP method, we purified
(ReliaPrep™ DNA Clean-Up and Concentration System,
Promega, USA) and sequenced (Sanger sequencing,
ThermoFisher Scientific, Germany) the 667bp (DEFB4A) and
445bp (DEFB4B) fragments from DNA of 43 healthy controls
from an independent explorative study cohort called EXACT (39).
Fragment purification from agarose gels was done by using the
protocol for DNA purification from gel slices as provided by the
manufacturer (Promega, USA). Sequencing revealed an accurate
overlap of the fragments with the respective references, including
the single nucleotide differences between the gene copies. The only
discrepancy was detected in the area of the 9 bp insertion of
DEFB4A, which appeared on the gel as a double band at the height
of the 667 bp fragment. Therefore, the double band may indicate
that the 9 bp insertion of DEFB4A is not present in both alleles
(Supplementary Figure 1A).
Statistical Analysis
Deviation from Hardy-Weinberg equilibrium (HWE) was
analyzed by chi-square test in the control group using PLINK
version 1.0 (40). All markers were in HWE (p>0.0001). We
generated Linkage Disequilibrium (LD) plots with Haploview
(41) and performed all further analyses with R software (Version
3.0.1). Normally distributed data are presented as mean with
standard deviation (SD) or 95% confidence interval (CI); non-
parametric data as median and interquartile range (IQR).
Differences between two groups were analysed using unpaired
Wilcoxon or Student’s t-test depending on their Gaussian
distribution. We evaluated associations of binary traits
primarily by logistic regression, stratified for farmer status as
previously described (33), using the survey-package in R
statistics5. Odds ratios (OR), 95% CI and p-values are reported
for association analyses. All p-values <0.05 were considered
statistically significant as the analyses were hypothesis-driven.
Only SNPs with a minimum of three minor allele carriers within
the cohort were analyzed. To investigate whether the presence or
absence of DEFB4A and DEFB4B was associated with health
status, we applied chi-square tests.
Murine Asthma Model Experiments
Mice
To assess preventive effects of hBD-2 in a model of inflammatory
airway disease, we used female BALB/c mice between 7 and 8
weeks of age (Charles River, Italy), which received food and
water ad libitum during the experiments. Animal-related
research followed the 2010/63/EU and National legislation
regulating the use of laboratory animals (Official Gazette 55/
13) and the Institutional Committee on Animal Research Ethics
(CARE-Zg). All animal experiments were performed according
to the specifications of the senior investigators (MK, JW, PN) by
Fidelta Ltd., Croatia.
Sensitization Procedure
For sensitization of the animals, a solution with 1 mg house dust
mite (HDM) protein/ml saline was prepared according to the
manufacturer’s instructions (33 mg HDM/vial; lot no 305469;
4www.ensembl.org 5https://www.jstatsoft.org/article/view/v009i08
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Greer, USA). This solution was combined with equal amount
(1:1 ratio) of complete Freund’s adjuvant (CFA) dissolved in
PBS. The animals were distributed according to sensitization and
treatment into three groups of 12 mice each (results section,
Figure 3). Mice from group 1 received subcutaneous
sensitization with saline containing CFA while groups 2 and 3
were sensitized subcutaneously with 100 µg HDM in 0.2 ml
saline and CFA at day 0. Group 1 did not receive any treatment,
while mice from group 2 received oral treatment with vehicle
(0.5% carboxymethylcellulose) at days 12, 13, and 14, and mice
from group 3 received oral hBD-2 at the same days. Sensitization
on day 0 was applied with a 100 µl Hamilton glass syringe and a
16G cannula. According to the sensitization and treatment
received, the groups were also called: Saline (1), vehicle/HDM
(2) or hBD-2/HDM (3).
Preparation and Dosing of the Test Compound
Human Beta-Defensin 2 (hBD-2)
Oral treatment with 1.2 mg/kg/day (0.4 mg/kg, 3 times a day)
hBD-2 (Novozymes, Denmark) started at day 12, 2 days prior to
the challenge with saline or HDM (day 14). The first daily dose
was given at approximately 8 a.m. each day, followed by two
additional administrations with 6-h intervals. The last dose was
administered orally on day 14, 1 h prior to the challenge, at the
volume of 10 ml/kg. The solutions for each dosing group had a
concentration of 0.04 mg/ml. Concentration of the used hBD-2
ampules was confirmed with a CV% < 0.5 (triplicates) and purity
was further verified to be 98.6% (UPLC). Endotoxins were below
0.004 EU/mg.
Asthma Induction and Prophylactic hBD-2
Administration
To induce allergic asthma, mice from groups 2 and 3 were
immunized subcutaneously on day zero with 100 µg HDM in 0.2
mL saline per animal; group 1 received 100 mL of CFA dissolved
in saline instead. On days 12 and 13, the mice received either
vehicle (group 2) or hBD-2, 0.4 mg/kg, orally, three times a day
(group 3). On day 14, only two doses of vehicle or hBD-2 were
administered, respectively. One hour after the last dose, mice
from groups 2 and 3 were intranasally challenged with 25 µg of
HDM in 50 mL of saline. No additional treatments following
challenge were carried out.
Airway Hyper-reactivity Measurements
At day 16, approximately 48 h after HDM application, 6 mice
from each group were challenged with methacholine. Immediately
after the challenge, lung resistance (cm H2O/mL/second) and
dynamic lung compliance (mL/cm H2O) were automatically
measured by a DSI’s Buxco® FinePointe™ RC system (DSI,
USA), and the results were computed by the RC system’s
software. Each mouse was anesthetized (0.2% Xylazine plus 5
mg/mL Narkamon dissolved in saline) and tracheostomized after
approximately 10 min for direct measurement of the respiratory
flow and lung pressure. Mice were then loaded into a
plethysmograph in a supine position, and a water or ethanol
filled tube was placed two-thirds down the esophagus. For artificial
ventilation, tracheal tubes were placed and fixed with tied suture,
(stroke volume: body weight/100, rate: 120 breaths/min).
Additionally, 0.1 mL of diluted ketamine (10 mg/mL) per 10 g
body weight was added intraperitoneal to each mouse. For airway
hyper-reactivity measurements, mice were initially exposed to
aerosolized PBS for the baseline value, followed by increasing
concentrations of 5 mL methacholine (3.125, 6.25, 12.5 and 25 mg/
mL), nebulized for 3 min before lung function was recorded. The
automated data acquisition software Finepointe™ (DSI’s Buxco)
was used to continuously record various basic parameters,
automatically generating resistance and dynamic compliance,
and performing statistical analysis. The data were calculated at
each time point, and lung resistance and compliance values were
shown as a curve for each group.
Bronchoalveolar Lavage Fluid and Lung Cell
Collection and Processing
Bronchoalveolar lavage fluid (BALF) was collected from all the
animals (n=36) 48 h after HDM challenge. In brief, the trachea of
each animal was cannulated, the lungs were washed with 3
volumes of cold PBS (0.4, 0.3 and 0.3 mL; 1 mL in total) and
the collected BALF was placed into an Eppendorf test tube for
each mouse. The tubes were centrifuged at 3,500 rpm and 4°C for
5 min, and cell pellets were re-suspended in 600 µL PBS by
vortexing. Total and differential cell counts in BALF were
determined on an automated haematological analyzer (Sysmex
XT-2000iV).
After the bronchoalveolar lavage, the lungs of all animals were
exposed and excised by opening the thorax, cutting down either
side of the sternum and ribs, and trimming back. The lungs were
removed from the thorax, snap frozen in liquid nitrogen and
stored at −80°C until preparation of the homogenates for
cytokine measurements. Frozen lungs were placed into PBS (1
volume tissue to 5 volumes PBS) containing a protease inhibitor
cocktail (Roche, Switzerland) and homogenized using an IKA
Turbo XT laboratory homogenizer (IKA, Germany). The tubes
were subsequently centrifuged for 10 min at 12,000 rpm and 4°C.
The clear supernatant was transferred to a new tube and stored at
−80°C until further analysis. The concentration of seven asthma-
related inflammatory cytokines, namely Interleukin (IL)-4, IL-5,
IL-6, IL-9, IL-13, IL-33, and tumor necrosis factor (TNF)-a, was
determined in lung homogenates of all mice using commercially
available ELISA kits, following the manufacturer’s instructions
(R&D systems, USA).
Statistical Analysis
For comparison of lung resistance and compliance, cell counts and
cytokine levels from the different groups, we used one-way ANOVA
with post-hoc t-test (Bonferroni corrected). Homogeneity of
variances was asserted using Levene’s Test, which showed that
equal variances could be assumed (all p-values > 0.24). Statistical
analyses were performed using SPSS Statistics (IBM, USA). All p-
values <0.05 were considered statistically significant.
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RESULTS
Mutations, Polymorphisms and Copy
Number Variants in the hBD-2 Region Are
Associated With Asthma and Atopy in
Children
The genes DEFB4A and DEFB4B, both coding for hBD-2, are
located on chromosome 8 (chr8p23.1) in close vicinity to five other
b-defensins (DEFB103, DEFB104, DEFB105, DEFB106, DEFB107),
all of which are aligned in a peculiar, mirror-like cluster with their
respective gene copies (Figure 1A). In the middle of this mirrored
region resides a stretch of approximately 50 kb of DNA, which
evaded all sequencing attempts so far due to massive repetition and
duplication (42).DEFB4B locates approximately 477 kb upstream of
DEFB4A in opposite reading directions, a general characteristic of
b-defensins in this region. The structure and sequence of both
DEFB4A and DEFB4B is highly similar (Figure 1B). The putative
promoter region of DEFB4A reaches 1,612 bp upstream from the
transcription start site and that of DEFB4B up to 1,874 bp. Overall,
61 out of 81 (75.3%) identified transcription factor binding sites of
the region 2,000 bp upstream are identical. Exonic sequences are
identical in 194 of 195 base pairs, leading to identical amino acid
sequences, as the single nucleotide difference in exon 1 is a silent
mutation. Intronic regions are 97.4% identical (1,629 out of 1,672
bp). The 3′ UTR and the first 48bp of the 5′ UTR from both genes
match by 100%. However, the 5′ UTR of DEFB4A (84 bp) is 48bp
longer than of the DEFB4B (36 bp).
Of the 458 SNPs annotated in the 500-kb region of interest in
public databases (43), 40 were of interest for genotyping within
10 kb downstream of both genes, including the 477 kb between the
genes, and followed the inclusion criteria described in detail in the
methods section. From those, 17 were located in or very close to
DEFB4A, 19 were described in or around DEFB4B, and four
additional SNPs locate in different regulatory regions between the
genes (Figure 1, Supplementary Table 3). Out of the 40 genetic
variants [7 in high LD (LD>0.8)], we were able to genotype 13 and
verify the existence of only 7 in our population with the applied
settings. This low genotyping success rate was specific for this
region, and thus contrasted with the high success rate in several
other chromosomal regions genotypedat the same time, in the same
cohort using identical design parameters (information available
upon request). The complex nature of the region and the close-to-
identical DNA sequence of the two genes could not be overcome by
alternative genotypingmethods applied. In case of a very lowminor
allele frequency (i.e., < 3 minor alleles) statistical analysis may lead
to spurious results and thus, ORs and CIs were not calculated.
For the seven genetic variants we could confirm, minor allele
frequencies and their association with asthma and allergy in our
study population are shown in Table 1. Overall, MAF was
magnitudes lower than expected when compared to CEU data.
Four out of seven present genetic variants were extremely rare yet
provided here for completeness. Indeed, all rare variants and two
out of three more common polymorphisms showed associations
with the outcomes under investigation (asthma and allergy, and
the combination thereof), hence exceeding stochastic expectations.
Due to the very low MAF, we could not assess the influence of
farm exposure on these associations in stratified analyses as
planned. In silico functional analyses showed that two associated
variants (rs6651513 and rs543538872) have putative functional
relevance: rs6651513 resides in an enhancer approximately 2kb
upstream of DEFB4B and correlates with DEFB4A and DEFB4B
expression, particularly in lung, skin, stomach, and esophagus
A
B
FIGURE 1 | DEFB4 locus on chromosome 8p23.1 with surrounding genes and pseudogenes (A) and location of the 40 selected SNPs for genotyping in GABRIELA
Ulm (B). (A) Red dots: A-copies of the b-defensin genes; orange dots: B-copies of the b-defensin genes; red and orange dots with black circle: DEFB4 genes. Blue
dots: unknown genes; yellow dots: FAM90A-pseudogenes; purple dots: PRR23-genes and OR7E-pseudogenes; brown dots: SPAG11-genes; green dots: HSPD1-
pseudogenes; grey dots: ZNF705-genes. The hatched rectangle in the middle represents a not yet sequenced 50 Kb area, which presents like a mirror in this
cluster. (B) positions of the selected SNPs for genotyping are shown as black vertical lines with numbers in relation to the position of DEFB4A and DEFB4B. Circled
numbers represent SNPs that were successfully genotyped. Black boxes refer to exonic regions, white boxes to UTRs, hatched boxes to putative promoter regions.
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mucosa (eQTL data provided by GTEx Portal6). Variant
rs543538872 locates within a DNaseI Hypersensitivity Cluster
901 bp upstream of DEFB4B (44) (UCSC genome browser7),
indicating that it could be part of the DEFB4B promoter region.
Sequence alignment of the DEFB4A and DEFB4B showed a
98% sequence overlap with very few single nucleotide differences
as mentioned above and depicted in alignment (Supplementary
Figure 1B). To distinguish between the two almost identical
genes, we used one single nucleotide difference in the intronic
region (Supplementary Figure 1C). In total, 155 out of 200
subjects (77.5%) selected from our strata of interest from the
GABRIELA Ulm cohort as described above (method section),
have a DEFB4A gene. DEFB4A was found significantly less
frequently in atopic individuals (p=0.012) and the same, but
non-significant trend, was found in asthmatics (Figure 2).
Prophylactic Oral Treatment With hBD-2
Reduces Effects of HDM Challenge in a
Murine Asthma Model
Asmultiple associations between genetic variations in theDEFB4A/
DEFB4Bgenecluster andasthmaandatopy inchildren suggest a role
of these genes in asthma and allergy development, we investigated
if hBD-2, due to its known functional entities, could help to explain
protection against asthma and allergy by farm exposure and
consumption of unprocessed milk on these farms. In an
established HDM asthma mouse model, we studied the impact of
orally administeredhBD-2 (or vehicleonly)prior toHDMchallenge
in 36 mice sensitized with either saline or HDM and assessed their
lung hyper-reactivity and inflammatory response (Figure 3).
We assessed lung resistance and dynamic compliance
between vehicle-treated (vehicle/HDM, group 2) and hBD-2-
treated mice (hBD-2/HDM, group 3) after HDM challenge. Six
animals per group initially received nebulization with PBS and
subsequently with four different concentrations of methacholine
(3.125, 6.25, 12.5 and 25 mg/mL). Vehicle-treated, HDM-
challenged mice exhibited a dose-dependent increase in lung
resistance paralleled by reduced lung compliance when
compared with both unchallenged, and hBD-2 treated, HDM
challenged mice (Figure 4). At the highest methacholine
concentrations, the vehicle/HDM group showed significantly
increased lung resistance compared to the hBD-2/HDM group
(p=0.02 at 12.5 mg/ml and p=0.025 at 25 mg/ml). Notably, mice
treated prophylactically with orally administered hBD-2 were
fully protected against HDM-induced lung resistance, despite
diminished lung compliance at the highest methacholine doses
(Figure 4).
Total and differential cell count in BAL fluid was conducted
48 h after HDM challenge. The number of total and specific
immune cells (eosinophils, neutrophils, macrophages and
lymphocytes) was significantly increased after HDM challenge
compared to saline-challenged mice, but no significant
differences were observed between vehicle-treated and hBD-2-
treated groups (Figure 5A). Thus, prophylactic oral treatment of
HDM-sensitized mice with hBD-2 did not influence cell counts
in BAL fluid after HDM challenge.
We next assessed hallmark asthma cytokines in lung
homogenates to evaluate if oral hBD-2 treatment mitigated the
pulmonary inflammation processes, hence explaining the relative
protection against deteriorated lung function as described above.
Vehicle-treated, HDM-challenged mice exhibited significantly
enhanced tissue concentrations of all tested cytokines (IL-4, IL-5,
IL-6, IL-9, IL-13, IL-33, and TNFa) compared to their PBS
challenged counterparts (Figure 5B). Again, prophylactic oral
administration of hBD-2 fully protected from HDM-induced
cytokine release (with IL-33 being the sole exception) and thus
significantly dampened pulmonary inflammation.
TABLE 1 | Genetic associations of SNPs in or nearby DEFB4A/B with asthma and atopy in the GABRIELA Ulm cohort (n=1,238).
MAF Asthma Atopy Atopic asthma Non-atopic asthma
No. SNP Minor allele CEU GABRIELA Ulm p-value OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value OR (95% CI)
17 rs533344477 C 0.005 0 – – – – – – – –
12 rs538653319 C 0.01 0 – – – – – – – –
3 rs538901702 T 0.005 0.0004 1.44-26 NA 5.67-33 NA 8.68-30 NA 4.59-23 NA
11 rs543538872 T 0.015 0.002 2.42-90 NA 0.169 4.03
(0.55–29.28)
9.14-82 NA 6.47-91 NA
2 rs546946128 A 0.005 0 – – – – – – – –
26 rs558364144 T 0.005 0 – – – – – – – –
35 rs558912368 A 0.005 0 – – – – – – – –
4 rs562192342 A 0.005 0 – – – – – – – –














22 rs62640720 G 0.328 0.0004 1.3-21 NA 5.22-28 NA 1.57-24 NA 1.15-18 NA
















SNP, single nucleotide polymorphism; CI, confidence interval; MAF, minor allele frequency; NA, not applicable; OR, odds ratio.
Bold values represent significant association of the SNP with the respective disease.
6https://www.gtexportal.org/
7https://www.genome.ucsc.edu/
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DISCUSSION
Genetic variations such as rare mutations, polymorphisms and
copy number variations in the DEFB4A/DEFB4B genetic cluster
associate with asthma and allergy in children. Furthermore, we
provide evidence that hBD-2 could contribute to protective farm
effects such as those mediated by the consumption of
unprocessed cow’s milk (12) when prophylactic administration
of oral hBD-2 mitigates pulmonary resistance and inflammation
in a mouse model of HDM-induced asthma.
Investigating the locus harboring DEFB4A and DEFB4B
specifically, we could confirm the high complexity of the region,
which is truly at the frontier of the technical resolution currently
possible in genetics. Numerous variants in the region evaded
genotyping by different techniques and others showed
dramatically lower MAF than predicted in the CEU population.
These differences may only in part be explained by population
characteristics but rather, are an expression of the high genetic
complexity of the locus. As described in more detail below, the
association with genetic variants in the hBD-2 locus for very
comprehensible reasons did not allow to specifically perform an
analysis stratified by farming exposure as originally planned.
The existence of two identical genes transcribing hBD-2
suggests a potential biological advantage in the capacity to
mount a strong hBD-2 response if needed. This situation
resembles the so called “cytokine gene cluster” on chromosome
5, containing the IL-4 and IL-13 coding genes, which are thought
to have arisen from a gene duplication and also share a locus
control region (45). Interestingly, IL-4 and IL-13 are both
necessary and complementary for a type-2 immune response
(46), as their functions have diverged over time, unlike that of the
two (almost) identical genes coding for hBD-2. Preservation of
genetic integrity in a coding sequence of a gene is always an
active effort, which hints at the biological importance of the gene
product. A similar situation exists for LL-37, an additional
defensin (own unpublished data).
A B
FIGURE 2 | Presence of DEFB4A in healthy (n=78) and diseased (n=122) subjects after RFLP assay for DEFB4A and DEFB4B. The diseased group include 41 non-
atopic asthmatics, 41 atopic asthmatics and 40 atopics. *p=0.012 (chi-square test).
FIGURE 3 | Prophylactic administration of hBD-2 in BALB/c mice and grouping according to sensitization and treatment. Challenge was carried out 1 h after the
last dose of saline or vehicle on day 14. AHR, airway hyper-reactivity; BALF, bronchoalveolar lavage fluid; CFA, Complete Freund’s Adjuvant; hBD-2, human beta-
defensin 2; HDM, house dust mite; i.n., intra-nasal; p.o., per oral; s.c., subcutaneous.
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Subjects with atopy (with and without asthma) are more
likely to lack DEFB4A in our study population. While all copy
number analyses in previous studies did not discriminate
between DEFB4A and DEFB4B, our approach explores for the
first time the two copies separately. Despite copy segregation
obtained by only a single nucleotide difference in the RFLP-like
experiments, subsequent sequencing confirmed specificity for
the respective copy. Still, it remains possible that DEFB4A is
present in a mutated, hitherto unannotated form, and thus not
identified in our analysis. In addition, some individuals in our
study cohort may not simply miss DEFB4A, but have duplicated
DEFB4B, similar to a homozygous state of a certain genotype
(here: BB instead of AB). Further mutations and polymorphisms
in the DEFB4A/DEFB4B cluster are also associated with a high
likelihood to influence the regulation of gene expression
according to in silico eQTL analyses. rs6651513 is located in an
enhancer region 2 kb upstream of DEFB4B and it seems to
negatively influence gene expression in the lung and skin and
positively influence the expression in stomach, esophagus, and
vagina, according to the online tool ensembl8. rs62640720 is also
located in a regulatory region (CTCF binding site, in promoter)
and positively influences the expression in vagina and skin, while
the expression in stomach, esophagus, and lung are negatively
affected. Assuming that increased expression of hBD-2 in the
lungs protects against asthma and allergies, these two mutations
seem to promote the development of asthma and allergies by
decreasing hBD-2 expression.
Yet, our genetic data on mutations have to be interpreted with
caution since some of the genotyped variants are extremely rare,
not allowing to calculate odds ratios. In the context of all the
evidence, including copy number variance and polymorphisms,
the sum of all the effects is rather suggestive if not convincing.
Taken together, these findings point toward the possibility that a
lack, or inadequate production, of hBD-2 could lead to an
increased susceptibility to asthma and allergy development,
under the premise of a potentially protective effect of hBD-2 in
these diseases.
Differences in copy numbers of the hBD-2 coding genes have
been reported to correlate with other chronic inflammatory
diseases. In the IBD, Morbus Crohn’s Disease, a decrease of
hBD-2 gene copy numbers has also been found (47), whereas in
psoriasis hBD-2 gene copy numbers seem to be increased (48).
This corresponds well with the more recent observation that
asthma and Crohn’s disease are comorbidities (49) and also
share genetic traits (50) while such overlaps are not common
with psoriasis. Interestingly, in comparison with psoriatic skin
lesions, hBD-2 is reduced in the skin of patients with atopic
dermatitis (51).
In addition to their shared lack of gene copies for the hBD-2
production, both asthma and Crohn’s Disease are influenced by
the same environments: early exposure to farm environment is
protective against the development of both (4–6, 10). We used
the GABRIELA Ulm cohort, which is based on children living in
rural areas, some with and some without farming contact, to
explore the connection between mutations in the hBD-2 coding
genes and asthma and allergy in a protective farm environment
for the development of inflammatory diseases. Our previous
studies have already suggested that genetic effects may be
modified by environmental exposures and in combination have
significant effects on the microbiome, explaining some of the
protective farm effects (13, 33). However, in these studies
the DEFB4A and DEFB4B genes were consistently neglected, as
the genotyping chips used did not cover this genomic region.
Unfortunately, the unexpectedly low MAF of all investigated
genetic variants in the locus did not allow for further stratified
analysis in our population due to its very low frequency, this kind
of analysis is even beyond the resolution of much larger datasets.
It would have been of interest to investigate gene by environment
effects in individuals exposed and non-exposed to farming
environments, but the absence of these analyses does not
hamper the overall conclusion, that genetic alterations in a
gene coding for a potential key player in the protective farming




FIGURE 4 | Lung resistance (A) and compliance (B) in 6 mice per group
48 h after saline or HDM challenge. Saline: Mice without treatment and
challenged with saline only. Vehicle/HDM: Mice prophylactically treated with
vehicle and challenged with HDM. hBD-2/HDM: Mice prophylactically treated
with hBD-2 and challenged with HDM. *significant difference (ANOVA with
post-hoc t-test; p<0.05) between vehicle treated and hBD-2–treated mice;
#significant difference (ANOVA with post-hoc t-test; p<0.05) between saline-
challenged and HDM-challenged mice. hBD-2, human beta-defensin 2; HDM,
house dust mite.
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general population. In contrast, this suggests that alterations of
hBD-2 expression are associated with asthma development
irrespective of protective environments.
As data from farm studies in asthma and allergy suggested an
independent protective effect of unprocessed farm milk
consumption, we hypothesized that if hBD-2 plays a role in
this mechanism, hBD-2 production cannot only occur in the
airways but also in the gut and based on the genetic data it should
be increased to exert its protective function. As farm effects are
only protective if they occur early in life, we further hypothesized
that such increased hBD-2 production should occur prior to
asthma development. As our initial goal was to investigate
the potential protective effect of hBD-2 against asthma, we
applied hBD-2 after sensitization and before challenge,
which is also in line with standard protocols for asthma
prevention experiments.
Our proof-of-concept mouse experiments support biological
relevance of prophylactic hBD-2.
Specifically, prophylactic oral hBD-2 treatment of HDM-
sensitized mice lowered the production of an array of classical
asthma associated cytokines, namely TNF-a, IL-4, IL-5, IL-6, IL-9,
and IL-13, in lung tissue of exposed mice subsequent to HDM
challenge and concomitantly reduced lung resistance after
methacholine-challenge. Since IL-4, IL-5, and IL-13 promote
airway eosinophilia, mucus overproduction and bronchial
hyper-responsiveness, it is likely that hBD-2 improves lung
resistance indirectly by lowering those cytokines in the lung
(52). Interestingly, hBD-2 had no effect on the cell counts in
BALF, suggesting at least in this model, that its immune regulatory
properties reflected in situ manipulation of pulmonary cytokine
release rather than affecting immune cell influx. These data align
well with a recent publication elucidating the immunomodulatory
potential of hBD-2 in experimental colitis as well as in
lipopolysaccharide-challenged mice and human peripheral blood
mononuclear cells (17). Unaffected cell counts in BALF of hBD-2-
treated mice seem exclusive to the oral administration route
described here for the first time. However, one could speculate
that the observed effect is due to possible impurities in the
production process of the protein, but our analyses showed a
high degree of purity. To completely rule out this possibility, an
additional control group, treated with a peptide of similar but
random amino acid composition like hBD-2, could be included in
future experiments. While intranasal administration of hBD-2
even in a therapeutic setting lessens pulmonary inflammation in
models of both steroid sensitive and steroid refractory asthma,
treatment efficacy in those models was mirrored by diminished
cell influx (27). Notably, intranasal administration of another
antimicrobial peptide, mCRAMP (murine orthologue of LL-37),
A
B
FIGURE 5 | Total and differential cell counts (eosinophils, neutrophils, macrophages, and lymphocytes) in bronchoalveolar lavage fluid (A) and concentration of
inflammatory cytokines (TNFa, IL-4, IL-5, IL-6, IL-9, IL-13, and IL-33) in lung homogenates of the 3 treatment groups (n=12 per group) (B). Saline: mice sensitized
with saline + CFA only (group 1). vehicle/HDM: mice sensitized with HDM at day 0, prophylactic treatment with vehicle at days 12 to 14, and challenge with HDM at
day 14 (group 2). hBD-2/HDM: mice sensitized with HDM at day 0, prophylactic treatment with hBD-2 at days 12 to 14, and challenge with HDM at day 14 (group
3). *p < 0.05 when compared to other groups (ANOVA with post-hoc t-test,). hBD-2, human beta-defensin 2; HDM, house dust mite.
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triggered asthma exacerbation in an allergic asthma mouse model
(53), hence suggesting a unique role of hBD-2 in this setting.
Obviously, one cannot directly translate these findings from
experimental mouse models to humans, and additional research
is still necessary to enhance our understanding of how hBD-2
may affect asthma development in humans. Considering the
respiratory challenges of asthmatic patients, it is nevertheless of
significant relevance that oral administration of hBD-2 effectively
mitigated pulmonary inflammation. Another future approach
could be taken by applying hBD-2 even before sensitization to
investigate a potential protective effect of hBD-2 against
allergy development.
Future studies are needed to define the pertinent crosstalk between
gut and lung in this setting and to establish if and how lung and gut
microbiome signatures may affect disease trajectories. To this end, it
was first shown in 2006 that colonic bacterial dysbiosis can alter the
immune response of the lung after pulmonary infection in mice (54).
It has further been demonstrated that constitutively expressed hBD-1
retains antimicrobial activity after proteolytic degradation by
gastrointestinal proteases (55), while other defensins, e.g. HD5 and
HNP4, not only preserve their antimicrobial activity upon
degradation, but even enhance antimicrobial potency and specificity
(56, 57). If this situation occurs in the context of orally administered
hBD-2, and the extent to which such phenomenon would enhance
transport of biologically active fragments from the gut to the lung,
remains to be described.
It is also possible that the potent immunomodulatory nature of
hBD-2 imprints systemic immunity to curb lung inflammation.
Indeed, a recent report with detailed immune assessment of 514
infants 18 months of age corroborate exaggerated systemic
immunity, in particular blood neutrophils and IL-13 producing
T cells, at the time of enrollment to predict both transient and
persistent childhood asthma (22). Early changes in the
microbiome of children developing asthma and allergy have also
been described recently (13). It is thus plausible that an aberrant
and weak hBD-2 response either due to genetically determined
limitations or a missing signal from the environment may play a
role in both an abnormal development of immunity and the
microbiome during childhood.
In conclusion, we demonstrate that hBD-2 and its coding genes,
DEFB4A andDEFB4B, play an important yet underestimated role in
the onset of asthma and atopy. Genetic alterations in the gene locus
or absence of DEFB4A significantly associate with the prevalence of
asthma and atopy in children while our mouse experiments clearly
indicate that hBD-2 can have a prophylactic role in preventing
features of allergic asthma. If and how these mechanisms could be
used to intervene in the development of childhood asthma and
allergy, still needs to be determined.
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